PREVALENCE AND MAGNITUDE OF OSTEOPENIA ASSOCIATED WITH INSULIN-DEPENDENT DIABETES-MELLITUS

被引:79
作者
KAYATH, MJ
DIB, SA
VIEIRA, JGH
机构
[1] Division of Endocrinology, Escola Paulista de Medicina, São Paulo
关键词
D O I
10.1016/1056-8727(94)90058-2
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The authors evaluated the prevalence, magnitude, and contributing factors for osteopenia in insulin-dependent diabetes mellitus (IDDM). We measured bone mineral density (BMD) in the lumbar spine and femoral region in 90 patients aged 18-54 years with IDDM using dual-energy x-ray absorptiometry. The blood-glucose control, insulin dosage, duration of disease, and presence of chronic complications of diabetes were evaluated. Serum ionized calcium, magnesium, phosphorus, alkaline phosphatase (ALP), 25-hydroxycholecalciferol, immunoreactive parathyroid hormone (iPTH), and urinary calcium, phosphorus, and hydroxyproline were also analyzed. Thirty-one patients (34%) were classified as having a reduced BMD (less than 2 SD below the mean). The comparison between normal and low BMD patients showed that the osteopenics had a tendency to be younger (median, 28 years versus 32 years), showed a higher mean plasma glucose (15.5 +/- 5.0 mmol/L versus 12.9 +/- 3.8 mmol/L; p = 0.018), longer duration of disease (11.2 +/- 2.1 years versus 5.0 +/- 1.3 years; p = 0.004), and needed a higher insulin dosage (56 +/- 17} U/day versus 43 +/- 16 U/day; p < 0.001). There was a positive correlation between mean glucose levels, duration of disease, insulin dosage, and bone-mass decrease. A higher incidence of chronic complications, mainly retinopathy (58% versus 25%) and neuropathy (52% versus 22%) was found in the low BMD group. There was no alteration of serum calcium, phosphorus, iPTH, 25-hydroxycholecalciferol, and urinary calcium and phosphorus. The ALP levels were significantly higher in the osteopenic group, and magnesium and hydroxyproline levels were lower in the whole diabetic group, but these measurements did not correlate with BMD reduction. Osteopenia should be considered as a chronic complication of poorly controlled patients, and is associated with longer disease duration and other IDDM chronic complications. (Journal of Diabetes and Its Complications 8;2:97-104, 1994.)
引用
收藏
页码:97 / 104
页数:8
相关论文
共 48 条
[1]
McNair, Madsbad, Christiansen, Christensen, Faber, Binder, Transbol, Bone loss in diabetes: Effects of metabolic state, Diabetologia, 17, pp. 283-286, (1979)
[2]
Hui, Epstein, Johnston, A Prospective Study of Bone Mass in Patients with Type I Diabetes*, The Journal of Clinical Endocrinology & Metabolism, 60, pp. 74-80, (1985)
[3]
McNair, Bone mineral metabolism in human type 1 (insulin-dependent) diabetes mellitus, Dan Med Bull, 35, pp. 109-121, (1988)
[4]
Wiske, Wentworth, Norton, Epstein, Johnston, Evaluation of bone mass and growth in young diabetics, Metabolism, 31, pp. 848-854, (1982)
[5]
Albright, Reifenstein, Parathyroid gland and metabolic bone disease: Selected studies, (1948)
[6]
Rosenbloom, Lezotte, Weber, Gudat, Heller, Weber, Klein, Kennedy, Diminution of bone mass in childhood diabetes, Diabetes, 26, pp. 1052-1055, (1977)
[7]
McNair, Madsbad, Christensen, Christiansen, Faber, Binder, Transbol, Bone mineral loss in insulin-treated diabetes mellitus: Studies on pathogenesis, Acta Endocrinol, 90, pp. 463-472, (1979)
[8]
Shore, Chesney, Mazess, Rose, Bargman, Osteopenia in juvenile diabetes, Calcif Tissue Int, 33, pp. 455-457, (1981)
[9]
De Leeuw, Abs, Bone mass and bone density in maturity-type diabetics measured by the I<sup>125</sup> photon-absorption technic, Diabetes, 26, pp. 1130-1135, (1977)
[10]
Mathiassen, Nielsen, Ditzel, Rodbro, Long-term bone loss in insulin-dependent diabetes mellitus, J Intern Med, 227, pp. 325-327, (1990)